VYVGART is positioned to become the first biologic effective across all MG subtypes and a first-line option in CIDP. The upcoming FDA decision on May 10, 2026 for seronegative gMG and planned sBLA for oMG represent near-term catalysts. Real-world switching data de-risk commercial adoption in CIDP. Investors should monitor regulatory outcomes and upcoming Phase 3 data for empasiprubart in CIDP.
ARGX drugs
ARGX drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 20 $834.45entry
- T+1 · 7mo ago −3.48%α −2.83% · $805.38
- T+5 · 7mo ago −6.08%α −6.99% · $783.74
- T+20 · 6mo ago −6.97%α −11.18% · $776.26
- T+60 · 4mo ago +3.41%α −3.36% · $862.93
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
argenx announced positive Phase 3 data from the ADAPT OCULUS and ADAPT SERON trials showing VYVGART's efficacy in ocular and seronegative myasthenia gravis, along with supportive data in CIDP. The company plans to submit a supplemental Biologics License Application (sBLA) for ocular MG and already has priority review for seronegative gMG, expanding VYVGART's potential market. Real-world data also support switching from IVIg to VYVGART Hytrulo in CIDP.
Key Facts
- Phase 3 ADAPT OCULUS study met primary endpoint (p=0.012) in ocular myasthenia gravis (oMG), showing statistically significant improvement in MGII PRO ocular scores at Week 4 vs placebo
- ADAPT SERON trial supports VYVGART's efficacy in AChR-Ab seronegative gMG (including MuSK+, LRP4+, triple seronegative), with FDA priority review granted and PDUFA date of May 10, 2026
- ADAPT Jr trial shows consistent MG-ADL improvements in adolescents with gMG
- ADHERE post hoc analysis shows 87.5% of treatment-naïve CIDP patients achieved early clinical benefit with VYVGART Hytrulo, median time to response 39.5 days
- Real-world data show 85.7% success rate switching from IVIg to VYVGART Hytrulo in 91 patients
- Planned sBLA submission to expand VYVGART label to oMG
Financial Impact
Significant revenue expansion potential as VYVGART gains broader label indications across multiple neuromuscular subtypes, including oMG (~20% of MG patients) and seronegative gMG
Risk Factors
- Regulatory delays or rejection of sBLA submissions despite positive data
- Competition from other biologics in neuromuscular indications
- Safety concerns with long-term use in broader populations
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001104659-26-045083 |
| Document: tm2612048d1_6k.htm | 0001104659-26-045083 |
| Document: 0001104659-26-045083-index-headers.html | 0001104659-26-045083 |
| Document: 0001104659-26-045083-index.html | 0001104659-26-045083 |
| Document: 0001104659-26-045083.txt | 0001104659-26-045083 |
Track record
23 reports on ARGX
7 of 8 bullish or bearish reports moved the stock their way by T+20. Best: +30.22% at T+60 after the Jun 3, 2026 report. 9 of 10 went positive at some point.
Filters
- Nov 9, 20267d ago 6-K Bullish 6/10 Entry $962.27 Now $950.95 −1.18% settles Dec 8
- Nov 9, 20267d ago 6-K Neutral 5/10 Entry $962.27 Now $950.95 −1.18% settles Dec 8
- Nov 9, 20267d ago Press Release Neutral 5/10 Entry $962.27 Now $950.95 −1.18% settles Dec 8
- Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $894.77 Now $950.95 +6.28% settles Dec 4
- Oct 29, 202618d ago Institutional Cluster Neutral 3/10 Entry $897.85 Now $950.95 +5.91% settles Nov 27
- Oct 22, 202625d ago 6-K Bullish 6/10 Entry $875.76 Now $950.95 +8.59% settles Nov 19
- Oct 19, 202628d ago 6-K Bullish 7/10 Entry $825.61 to $950.95 Now $950.95 +15.18% ▲ +15.18% +18.64% vs SPY
- Oct 8, 20265w ago 6-K Mixed 6/10 Entry $818.63 to $931.38 Now $950.95 +16.16% ▲ +13.77% +19.06% vs SPY
- Sep 29, 20266w ago 6-K Bullish 6/10 Entry $970.66 to $871.52 Now $950.95 −2.03% ▼ −10.21% −10.87% vs SPY
- Sep 10, 20269w ago Institutional Cluster Mixed 5/10 Entry $984.04 to $818.63 Now $950.95 −3.36% ▼ −16.81% −18.93% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers